About - Practical Recommendations in Immuno and Molecular Oncology (PRIMO)

The 2022 Annual
PRIMO Meeting Agenda

The PRIMO meeting Co-Chairs, Steering Committee, and Education Committee are working hard to curate an agenda to meet the educational needs of all attendees and will focus on the following key areas:

  • Practical considerations of applying biomarkers and targeted therapy
  • Integration of immunotherapy, with a focus on novel management approaches
  • Patient selection, as well as timing and sequencing of therapy
  • Dealing with important trends, such as big data and defining value in cancer care
NOTE: All times listed are in Central Standard Time (CST)
3:00 PM – 3:05 PM
Meeting Welcome from Cancer Expert Now (Non-CME/CE)
3:05 PM – 3:10 PM
History of Women in Oncology (Non-CME/CE)
3:10 PM – 3:20 PM
Conference Overview and Objectives
Hematologic Malignancies - Julie Vose  /  Sagar Lonial
3:20 PM – 3:40 PM
Indolent and Aggressive NHL Including CAR-T
3:40 PM – 4:00 PM
Smoldering MM and Early Therapy vs Observation
4:00 PM – 4:20 PM
AML/MDS: Update on Therapy
Product Theater
4:20 PM – 5:20 PM
Product Theater (Non-CME/CE)
Hematologic Malignancies (cont.)
5:20 PM – 5:40 PM
CLL: What is the Best Initial Therapy for a Newly Diagnosed patient?
5:40 PM – 6:00 PM
Update on ALL Therapy
6:00 PM – 6:20 PM
Break I Visit the Virtual Exhibits
Gastrointestinal Malignancies – Rachna T. Shroff
6:20 PM – 6:40 PM
Colon Cancer - Divide and Conquer
6:40 PM – 7:00 PM
Hot Topics in Pancreatic and Biliary Cancer
7:00 PM – 7:20 PM
Five Years In; How Far Reaching Have Biosimilars Been in the US?
Product Theater
7:20 PM – 8:20 PM
Product Theater (Non-CME/CE)
Closing Remarks
8:20 PM – 8:25 PM
Close of meeting day 1

3:00 PM – 3:05 PM
Meeting Welcome from Cancer Expert Now (Non-CME/CE)
3:05 PM – 3:10 PM
History of Women in Oncology (Non-CME/CE)
3:10 PM – 3:20 PM
Conference Overview and Objectives
Melanoma, Skin Cancers, RCC – Shane Morita
3:20 PM – 3:40 PM
Melanoma: Keeping Up With the Data
3:40 PM – 4:00 PM
Sarcoma: Where are We Making Progress?
4:00 PM – 4:20 PM
Medical Therapy for Head and Neck Cancers: Current Status
Product Theater
4:20 PM – 5:20 PM
Product Theater (Non-CME/CE)
GU Cancers - Sanjiv Agarwala
5:20 PM – 5:40 PM
Bladder Cancer: Sequencing Therapeutic Choices
5:40 PM – 6:00 PM
RCC: A Surfeit of Riches – What’s a Clinician to Do?
6:00 PM – 6:20 PM
Impact of COVID-19 on Cancer Care
6:20 PM – 6:40 PM
Break I Visit the Virtual Exhibits
Lung - Paul A. Bunn
6:40 PM – 7:00 PM
Immunotherapy for Advanced NSCLC.
7:00 PM – 7:20 PM
Matching Drugs to Targets in NSCLC
7:20 PM – 7:40 PM
Therapeutic Advances in SCLC
Product Theater
7:40 PM – 8:40 PM
Product Theater (Non-CME/CE)
Closing Remarks
8:40 PM – 8:45 PM
Close of meeting day 2

3:00 PM – 3:05 PM
Meeting Welcome from Cancer Expert Now (Non-CME/CE)
3:05 PM – 3:10 PM
History of Women in Oncology (Non-CME/CE)
3:10 PM – 3:20 PM
Conference Overview and Objectives
Breast Cancer – Hope S. RugoHope S. Rugo, MD
3:20 PM – 3:40 PM
New Directions in the Treatment of ER+ Breast Cancer
3:40 PM – 4:00 PM
Updates in the Treatment of HER2+ Breast Cancer
4:00 PM – 4:20 PM
Triple Negative Breast Cancer: Immunotherapy and Novel Agents
Product Theater
4:20 PM – 5:20 PM
Product Theater (Non-CME/CE)
Breast Cancer (CONT.)
5:20 PM – 5:40 PM
Managing the Toxicity of Endocrine Therapy: Diet, Exercise, Sexual Health
5:40 PM – 6:00 PM
Genomics to Guide Therapy in Early and Late Stage Breast Cancer
Hope S. Rugo, MD
6:00 PM – 6:20 PM
Metastatic Survivorship Care
6:20 PM – 6:40 PM
SITC on Practical Recommendations Including Reimbursement Issues for Immunotherapy
6:40 PM – 7:00 PM
Break | Visit the Virtual Exhibits
Other Women’s Cancers
7:00 PM – 7:20 PM
Ovarian Cancer: PARP, Bevacizumab, Immunotherapy
7:20 PM – 7:40 PM
Cervical and Uterine Cancer Updates
Closing Remarks
7:40 PM – 7:50 PM
Closing Remarks

We acknowledge commercial support from Taiho Oncology, Exelixis, Pfizer, AstraZeneca, and Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Registration

Registration Type Early
01/01/2021 - 08/31/2021
Regular
09/01/2021 - 12/31/2021
Late
01/01/2022 - 02/15/2022
One-day
pass
Physician
$445.00
$545.00
$645.00
$250.00
Allied Health
$345.00
$445.00
$545.00
$200.00
Resident/Fellow
$295.00
$395.00
$495.00
$175.00
Industry
$995.00
$1,195.00
$1,595.00
$450.00

Join your colleagues and explore key developments in cancer care over the past 12 months as well as the anticipated advances that you and your patients will likely see in the upcoming year.

Target Audience

This activity has been designed to meet the educational needs of Academic and Community Practitioners, as well as Registered Nurses and Advanced Practice Registered Nurses, Pharmacists and Physician Assistants from all oncology specialties, treating all disease sites involved in the care of patients with cancer.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Describe the rationale for mechanisms of action for molecular targeted and immunologic therapies used to treat cancer today;
  • Summarize recent advances in targeted and immunologic treatment of hematologic malignancies and solid tumors;
  • Identify patients who are appropriate candidates for targeted and immunologic therapies;
  • Implement strategies from a healthcare team approach to reduce treatment-related toxicities, and optimize patient outcomes;
  • Discuss promising targeted and immunologic approaches being tested in late-stage clinical trials.

PRIMO 2020
at a Glance

26 Conference Sponsors

THE PRACTICAL RECOMMENDATIONS IN IMMUNO AND MOLECULAR ONCOLOGY MEETING is a unique opportunity to receive CME/CE credits while staying ahead of the latest advances in immuno and molecular oncology.

The Annual PRIMO Meeting is designed to summarize key developments in cancer care over the past 12 months and features anticipated advances that you and your patients will likely see in the upcoming year.

Accredited by:

MEC Logo

Accreditation and Credit Statements

Jointly Accredited Provider Logo
In support of improving patient care, The Medical Educator Consortium is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
IPCE Credit Logo
This activity was planned by and for the healthcare team, and learners will receive 13.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physician

The Medical Educator Consortium designates this live activity for a maximum of 13.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME MOC Logo
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing

The Medical Educator Consortium designates this activity for 13.5 contact hours.

Pharmacist

This Application-based activity has been approved for 13.5 contact hours (1.3 CEU) by The Medical Educator Consortium. The Universal Activity Number for this program is JA4008179-0000-21-009-L01-P. Your CE credits will be electronically submitted to CPE Monitor® within 60 days upon successful completion of the activity.

Physician Assistant

AAPA Cat1 CME logo

The Medical Educator Consortium has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 13.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

DISCLOSURE POLICY

The Medical Educator Consortium (MEC) adheres to the Joint Accreditation Criteria and the ACCME Standards for Integrity and Independence in Accredited Continuing Education. As a Joint Accreditation (JA) provider, decisions in the planning process of this conference were made free of the control of ineligible companies. All persons that will be in a position to control the content of the CME/CE Activity are required to disclose all relevant financial relationships. MEC has implemented a mechanism to identify, mitigate and disclose relevant financial relationships prior to the education activity being delivered to learners. A Disclosure Index document outlining this information will be made available to participants prior to the educational activity. The source of all support from ineligible companies will also be disclosed to learners prior to the beginning of the educational activity. CME/CE activities must be balanced, independent of commercial bias, and designed to improve quality in health care. All recommendations involving clinical medicine must be based on evidence within the medical profession.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contradictions, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contradictions and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.